Ann: Notice of Annual General Meeting/Proxy Form, page-29

You are spot on @What A Gas. I'll focus in on Life Sciences.

Key Question 1:
A) Why hasn't AnteoTech made significant sales of their Eugeni Covid-19 world class RAT (Sensitivity 97.3% Specificity 99.6%) during the Pandemic?

We know that:
B) ADO has one of the most accurate Covid-19 rapid tests in the world = immediate opportunity since EuGeni launch 7 months ago
C) rapid testing is still being used across the globe (just look at Quidel), incl. the locations of our distributors = immediate opportunity
D) the EuGeni platform will be able to incorporate many more tests down the track = future potential

Where to from here?
- in June 2020 I wrote to the Board and suggested we add a Commercial Director to the Anteo team. Objectives for this role is to drive the Got To Market strategy incl. marketing and sales. I am struggling to understand why this did not / has not happened. I believe that this contributes heavily to A) above. Given we have $20m in the bank for the purpose of driving growth, I struggle to understand rationale as to why this key role for commercialisation is missing. As a result, we remain a R&D type company and not a business. Signing up a network of distributors is great, but not the entire solution for a Go To Market strategy, as evidenced by lack of significant sales to date
- Some questions that I am interested in evidence based responses from the CEO include: is it the platform approach that is a constraint to commercialisation as @mimmo suggested? If so what is the company doing to address / pivot? What is the addressable market for EuGeni at this stage in the pandemic and what are the priorities to drive shareholder return?


Key Question 2:
E) What is the Go To Market strategy for commercialising the Covid-19 Flu A/B multiplex test?

We know that:
F) In March '21, Derek committed to the market that the Clinical Trial of the Covid-19 Flu A/B multiplex test would kick off August '21. This is 2 months ago
G) We must have some key learnings from the EuGeni experience that can be harnessed for improvements to speed and effectiveness of the commercialisation of the Covid-19 Flu A/B multiplex test
H) N Hemisphere Flu season has started and peaks Dec-Feb

Where to from here?
- To commercialise the Covid-19 Flu A/B multiplex test, we need to have the product locked down by now, trials concluded by now, regulatory approvals by now and a clear Go To Market strategy by now. If any of these key steps are not completed at this stage, we will unlikely meet the N Hemisphere Flu season on time and miss the boat

I take your point @slippin that without Derek we would not be here at this SP or stage (I do also believe that there are other factors at play, but somewhat agree with you). However, I am asking questions like "what else", "what changes", "what enhancements" can AnteoTech make to their team to commercialise. Which after all, is why the company exists - to bring quality diagnostic tests to the market.

Moose